New codes needed for chronically ill pts

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 6
Volume 17
Issue 6

I recently attended a healthcare conference titled “Leadership Summit on Evidence-Based Medicine” in Alexandria, Virginia. As you know, private industry, insurance companies, and the government are trying to develop an evidence-based medicine approach to help check the growth of healthcare expenditures.

I recently attended a healthcare conference titled “Leadership Summit on Evidence-Based Medicine” in Alexandria, Virginia. As you know, private industry, insurance companies, and the government are trying to develop an evidence-based medicine approach to help check the growth of healthcare expenditures.

The esteemed speakers’ overarching conclusion was that there is currently no independent measurement of evidence-based medicine.

As you can guess, I was one of only a few speakers representing the interests of oncologists. After 3 days, I finally had an opportunity to comment. From the oncology perspective, my solution was simple: Create level six, seven, and eight E&M codes for chronically ill patient care. These codes could be utilized by any physician in any specialty providing chronic care.

For oncology, these new codes would solve the issue surrounding the failed lobbying for oncology treatment planning codes. Treatment planning never happened-even at our urging with a detailed proposal including documentation. As the AMA RUC Committee has stated in denying the new codes: Oncology treatment planning is recognized in the level five services.

These new level six, seven, and eight codes for the management of chronically ill patients would allow oncologists to be compensated for the complexity of their services and would clearly define the outcome measurements needed for applying evidence-based medicine to the treatment of these patients.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
2 experts in this video
2 experts in this video
Extravasation with beta emitters may elicit more drastic adverse effects due to their higher radiation dose.
Increasing the use of patient-reported outcomes may ensure that practitioners can fully ascertain the impact of treatment for rare lymphomas.
Photographic and written documentation can help providers recognize inflammatory breast cancer symptoms across diverse populations.
The use of guideline-concordant care in breast cancer appears to be more common in White populations than Black populations.
2 experts are featured in this series.
Related Content